Vivozon Pharmaceutical Co Ltd

Vivozon's capital structure shows a debt-to-equity ratio of 0.58, indicating moderate leverage, while its liquidity position is characterized by a current ratio of 0.43, suggesting potential short-term liquidity constraints. The company's price-to-book ratio is 2.55, and its price-to-tangible-book ratio is also 2.55, reflecting a market valuation that is above book value. However, the company's enterprise value to EBITDA is negative at -9.38, and its enterprise value to revenue is 3.78, indicating a challenging valuation environment. Profitability metrics for Vivozon are weak, with a return on equity of -0.4462 and a return on assets of -0.1959, both significantly below the industry median. The company reported a net loss of 32,424,112,970 KRW and an operating loss of 23,914,058,500 KRW, which is a significant deviation from the industry's preferred metrics of profitability and returns. The company's revenue is primarily concentrated in its domestic market, with no disclosed segment or geographic breakdown. This lack of diversification may expose the company to regional economic fluctuations. The company's recent financial performance shows a decline in revenue, with the last actual revenue reported at 46,003,000,000 KRW, which is lower than the revenue of 59,343,216,710 KRW. The company's growth trajectory is uncertain, with a net loss and negative operating cash flow of -6,868,916,470 KRW. The company's capital expenditure of -2,212,951,290 KRW indicates a reduction in investment, which may affect future growth. The company's free cash flow is negative at -30,111,475,880 KRW, which may limit its ability to fund operations and growth initiatives. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability. The company's financial statements and risk assessments do not provide evidence of recent strategic shifts or major operational changes.